Skip Navigation Links
BWH Division of Women's and Perinatal Pathology
Program Information
Consultation Services
Fellowship Training
Staff Directory/Profiles
Center For Uterine Cancer/Research Programs
Other Links
Staff Only
Contact Us
Bradley J. Quade, M.D., Ph.D.

Associate Professor of Pathology (HMS)
Internet Developer (www.obgynpath.org)
Associate Pathologist

Email: bquade@partners.org
(617) 732-7980
(617) 738-6996

Division of Women's and Perinatal Pathology
Department of Pathology
Brigham and Women's Hospital
75 Francis Street
Boston, MA 02115


Educational Background

Medical/Graduate Education

1990 M.D. Washington University at St. Louis
1990 Ph.D. Washington University at St. Louis

Post-doctoral Fellowship(s)

1990-1992 Residency in Pathology Brigham and Women's Hospital
1992-1994 Fellowship in Women's and Perinatal Pathology Brigham and Women's Hospital

Board Certification

1994 American Board of Pathology

Academic Interest(s)

Uterine Smooth Muscle Neoplasms

     The first major focus of the Quade laboratory is the pathobiology of mesenchymal neoplasms arising in the female genital tract. These tumors range from extremely common leiomyomata to rare, yet often fatal leiomyosarcomas and unusual, quasi-malignant proliferations. The goal is to identify the molecular factors that cause these tumors and determine their malignant potential. Previously, Dr. Quade and colleagues have shown that disseminated peritoneal leiomyomatosis, a clinically benign condition in which hundreds of fibroid-like tumorlets stud the peritoneum and omentum, is in fact a clonal metastatic process. In addition, they have showed that intravenous leiomyomatosis is associated with t(12;14) and aberrant expression of HMGA2. HMGA2, a non-histone chromatin protein, also is rearranged in a number of benign mesenchymal neoplasms including uterine leiomyomata. In other studies, they have sought to identify molecular changes that distinguish benign and malignant uterine smooth muscle tumors. First, they have shown that loss of heterozygosity (LOH) for chromosome 10, particularly the q arm, is very frequent in leiomyosarcomas, but not in leiomyomata. Second, they have developed several immunohistochemical markers (h-caldesmon and CD-10) as useful tools in the differential diagnosis of endometrial stromal neoplasms and cellular smooth muscle neoplasms. Third, transcriptional profiling has defined a small number of genes that segregate myometrium and typical leiomyomata from uterine leiomyosarcoma, and interestingly, atypical leiomyomata. Fourth and most recently, they are characterizing leiomyomata with t(10;17)(q22;q23). The 10q22 breakpoint falls within MORF (MYST4), a histone acetyltransferase, and appears to be similar to rearrangements found in acute myelomonocytic leukemias.

     The second major focus of the laboratory is the identification of genes important in human development. The Quade laboratory is part of a multi-disciplinary, multi-laboratory program project known as the Developmental Genome Anatomy Project. Balanced de novo chromosomal rearrangements are associated with congenital anomalies in some individuals. The working hypothesis is that these rearrangements result in the disruption or dysregulation of genes required for proper development. Phenotypes of DGAP cases that would be of potential interest to trainees include uterine anomalies (e.g., bifid uterus), hypogonadism, and ovarian cysts.

Publication List and Abstracts (from PubMed/National Library of Medicine)

For More Information:

http://dgap.harvard.edu

http://www.fibroids.net


[top]